WCLC 2021 saw lots of discussion surrounding the treatment of patients with ALK-positive lung cancer. Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, shares some of the latest trends and trial data from the ALK-positive field. Prof. Peled discusses the GLASS retrospective study of lorlatinib in previously treated patients with ALK/ROS1+ non-small cell lung cancer (NSCLC), which showed a significant survival benefit for both patient groups and was well tolerated. There is a pattern of next generation ALK tyrosine kinase inhibitor (TKIs) making their way to first-line use. For example, alectinib has shown superior results to crizotinib in untreated ALK+ NSCLC in the ALEX trial (NCT02075840), as did brigatinib in the ALTA-1L trial (NCT02737501). Additionally, the ongoing CROWN study (NCT03052608) is looking into lorlatinib versus crizotinib in first line treatment of ALK+ NSCLC. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.